FBLG - FibroBiologics Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

fibrobiologics.com - graphic logo of issuer FBLG

This EV/EBITDA chart, which currently stands at 0.00, is based on the application of unique cellular technologies to combat disc degeneration and sclerosis. This price action is supported by the recruitment of leading biologists and the retention of R&D personnel through stock options. Consequently, FibroBiologics, Inc. (FBLG) is leveraging the expansion of its patent portfolio to secure a dominant position in the regenerative medicine sector.

FibroBiologics - FBLG Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/12/2026)

fibrobiologics.com (FBLG) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart FibroBiologics|FBLG - Price Target Chart
- market capitalization statistics:
Market Value FibroBiologics, Inc.|FBLG - Company Buyout Price
- book value of equity indicators:
Book Value per Share FibroBiologics|FBLG - Net Asset Value|Market Capitalization to Book Value Ratio fibrobiologics.com|FBLG - Company Total Asset Base
- company liabilities and liquidity data:
Total Debt to Capital FibroBiologics, Inc.|FBLG - Long-Term Debt to Equity|Short-Term Debt to Equity FibroBiologics|FBLG - Aggregate Debt Obligations|Debt to Book Capitalization Ratio FibroBiologics, Inc.|FBLG - Long-Term Debt|Company Short-Term Debts FibroBiologics|Quick Ratio fibrobiologics.com
- financial results and valuation multiples details:
FBLG - Net Financial Result|Expected Profit FibroBiologics, Inc.|FBLG - Market Cap to Earnings|Future Price to Earnings FibroBiologics|FBLG - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroBiologics, Inc.|FBLG - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) FibroBiologics|FBLG - Net earnings per share for the trailing year|Quarterly EPS earnings growth fibrobiologics.com|FBLG - Expected net earnings per share growth this year|Earnings growth forecast for next year FibroBiologics, Inc.
Summary company analysis:FBLG (FibroBiologics Corp)
Product sample of FibroBiologics

The EV/EBITDA multiple determines the total value of a business relative to its operating profit before depreciation, taxes, and interest, allowing for an assessment of real capital regardless of the financing structure. By analyzing the EV/EBITDA metric inclusive of depreciation and debt, investors determine the fair value of FibroBiologics, Inc. (FBLG) assets, taking into account the extensive expenditures on the patent portfolio required for the subsequent global scaling of cellular technologies.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mesoblast Corp MESO|Lineage Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SRZN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Cryo-Cell International CCEL|LGVN: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio BRTX (BioRestorative Therapies, Inc.)|CELZ (Creative Medical Technology Holdings, Inc.) - EV/EBITDA Multiple